Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · IEX Real-Time Price · USD
2.060
-0.110 (-5.07%)
At close: Jul 2, 2024, 4:00 PM
2.070
+0.010 (0.49%)
After-hours: Jul 2, 2024, 7:23 PM EDT
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for XERS stock have an average target of 4.63, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 124.76% from the current stock price of 2.06.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 31, 2024.
Analyst Ratings
The average analyst rating for XERS stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +191.26% | May 31, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | +45.63% | May 10, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $5 | Buy | Initiates | $5 | +142.72% | Mar 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5.5 → $6 | Strong Buy | Maintains | $5.5 → $6 | +191.26% | Mar 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5.5 | Strong Buy | Maintains | $6 → $5.5 | +166.99% | Nov 13, 2023 |
Financial Forecast
Revenue This Year
188.70M
from 163.91M
Increased by 15.12%
Revenue Next Year
224.77M
from 188.70M
Increased by 19.11%
EPS This Year
-0.42
from -0.45
EPS Next Year
-0.20
from -0.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 199.3M | 245.2M | 293.6M | 335.4M | 375.8M |
| Avg | 188.7M | 224.8M | 267.9M | 314.2M | 364.1M |
| Low | 173.3M | 192.6M | 236.2M | 291.2M | 348.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 21.6% | 30.0% | 30.6% | 25.2% | 19.6% |
| Avg | 15.1% | 19.1% | 19.2% | 17.3% | 15.9% |
| Low | 5.7% | 2.1% | 5.1% | 8.7% | 11.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.36 | -0.08 | 0.20 | 0.50 | 0.72 |
| Avg | -0.42 | -0.20 | 0.06 | 0.32 | 0.54 |
| Low | -0.52 | -0.39 | -0.05 | 0.20 | 0.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 697.0% | 123.7% |
| Avg | - | - | - | 412.1% | 66.9% |
| Low | - | - | - | 209.9% | 12.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.